Any feedback?
Literature summary for 3.4.14.5 extracted from
- Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus (2007), Pharmacotherapy, 27, 1163-1180.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | DPP-IV inhibitors appear to have excellent therapeutic potential in the management of type 2 diabetes as monotherapy or in combination with existing agents, such as metformin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with sustainable reductions in glycosylated hemoglobin levels and relatively few adverse effects | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | - |
Homo sapiens |  |
| vildagliptin | - |
Homo sapiens | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
